Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

Clinical Microbiology and Infection, Supplement

Volumn 11, Issue 4, 2005, Pages 17-32

  Rossolini, G M ^a   Mantengoli, E ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Antibiotic resistance; Control; Pseudomonas aeruginosa; Review; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOPERAZONE; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHEM DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MACROLIDE; MEROPENEM; MONOBACTAM DERIVATIVE; NETILMICIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TRIMETHOPRIM; UREIDOPENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL MUTATION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; ENZYME DEGRADATION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT PLANNING; URINARY TRACT INFECTION;

PSEUDOMONAS AERUGINOSA;

EID: 21744451018     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01161.x     Document Type: Review

References (178)

1. Goldberg JB. Pseudomonas: global bacteria. Trends Microbiol 2000; 8: 55-57.
2. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000; 406: 959-964.
3. Morrison AJ, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984; 6: S627-S642.
4. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th edn. Philadelphia: Churchill Livingstone, 2000: 2310-2335.
5. Anonymous. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from October 1986 to April 1998, issued June 1998. Am J Infect Control 1988; 26: 522-533.
6. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. J Am Med Assoc 1995; 274: 639-644.
7. Rajashekaraiah KR, Rice TW, Kallick CA. Recovery of Pseudomonas aeruginosa from syringes of drug addicts with endocarditis. J Infect Dis 1981; 144: 482.
8. Fisher MC, Goldsmith JF, Gilligan PH. Sneakers as a source of Pseudomonas aeruginosa in children with osteomyelitis following puncture wounds. J Pediatr 1985; 106: 66-609.
9. Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 1988; 85: 391-398.
10. Bottone EJ, Perez Jr AA. Pseudomonas aeruginosa folliculitis acquired through use of a contaminated loofah sponge: an unrecognized potential public health problem. J Clin Microbiol 1993; 31: 480-483.
11. Holland SP, Pulido JS, Shires TK, Costerton JW. Pseudomonas aeruginosa ocular infections. In: Fick RB Jr, ed. Pseudomonas aeruginosa: The Opportunist. Boca Raton: CRC Press, 1993: 159-176.
12. Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis 1990; 12: 693-702.
13. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000; 31: 1349-1356.
14. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109: 1019-1029.
15. Mayhall CG. Nosocomial pneumonia. Diagnosis and prevention. Infect Dis Clin North Am 1997; 11: 427-457.
16. Rello J, Rue M, Jubert P et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25: 1862-1867.
17. Anonymous. National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986 to April 1996, issued May 1996. Am J Infect Control 1996; 24: 380-388.
18. Bouza E, Burillo A, Muñoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect 2002; 8: 265-274.
19. Mousa HA. Aerobic, anaerobic and fungal burn wound infections. J Hosp Infect 1997; 37: 317-323.
20. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621-1629.
21. Gallagher PG, Watanakunakorn C. Pseudomonas bacteremia in a community teaching hospital 1980-1984. Rev Infect Dis 1989; 11: 846-852.
22. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2: 211-215.
23. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial blood-stream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33: 947-953.
24. Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 1993; 17(suppl 2): S322-S328.
25. Aquino VM, Pappo A, Buchanan GR, Tkaczewski I, Mustafa MM. The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 1995; 14: 140-143.
26. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
27. Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999; 341: 893-900.
28. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 2000; 19: 915-925.
29. Diekema DJ, Pfaller MA, Jones RN et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States. Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999; 29: 595-607.
30. Bernardini J, Piraino B, Sorkin M. Analysis of continuous ambulatory peritoneal dialysis-related Pseudomonas aeruginosa infections. Am J Med 1987; 83: 829-832.
31. Davies JC. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. Paediatr Respir Rev 2002; 3: 128-134.
32. Dropulic LK, Leslie JM, Eldred LJ, Zenilman J, Sears CL. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis 1995; 171: 930-937.
33. Vidal F, Mensa J, Martinez JA et al. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 1999; 18: 473-477.
34. Manfredi R, Nanetti A, Ferri M, Chiodo F. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur J Epidemiol 2000; 16: 111-118.
35. Ramphal R, Pier GB. Role of Pseudomonas aeruginosa mucoid exopolysaccharide in adherence to tracheal cells. Infect Immun 1985; 47: 1-4.
36. Doig P, Todd T, Sastry PA et al. Role of pili in adhesion of Pseudomonas aeruginosa to human respiratory epithelial cells. Infect Immun 1988; 56: 1641-1646.
37. Prince A. Adhesins and receptors of Pseudomonas aeruginosa associated with infection of the respiratory tract. Microb Pathogen 1992; 13: 251-260.
38. Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J Ind Microbiol 1995; 15: 162-168.
39. Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3: 23-35.
40. Drenkard E, Ausubet FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-743.
41. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66: 86-92.
42. Berka RM, Vasil ML. Phospholipase C (heat-labile hemolysin) of Pseudomonas aeruginosa: purification and preliminary characterization. J Bacteriol 1982; 152: 239-245.
43. Kharami A, Bibi Z, Nielsen H, Hoiby N, Doring G. Effect of Pseudomonas aeruginosa rhamnolipid on human neutrophil and monocyte function. APMIS 1989; 97: 1068-1072.
44. Lutz F, Xiong G, Jungblut R, Orlik-Eisel G, Gobel-Reifert A, Leidolf R. Pore-forming cytotoxin of Pseudomonas aeruginosa: the molecular effects and aspects of pathogenicity. Antibiot Chemother 1991; 44: 54-58.
45. Read RC, Roberts P, Munro N et al. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol 1992; 72: 2271-2277.
46. Komori Y, Nonogaki T, Nikai T. Hemorrhagic activity and muscle damaging effect of Pseudomonas aeruginosa metalloproteinase (elastase). Toxicon 2001; 39: 1327-1332.
47. Pollack M. Pseudomonas aeruginosa exotoxin A. N Engl J Med 1980; 302: 1360-1362.
48. Pollack M. The role of exotoxin A in Pseudomonas disease and immunity. Rev Infect Dis 1983; 5(suppl 5): S979-S984.
49. Nicas TI, Bradley J, Lochner JE, Iglewski BH. The role of exoenzyme S in infections with Pseudomonas aeruginosa. J Infect Dis 1985; 152: 716-721.
50. Hwang J, Fitzgerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48: 129-136.
51. Coburn J. Pseudomonas aeruginosa exoenzyme S. Curr Top Microbiol Immunol 1992; 175: 133-143.
52. Van Delden C, Iglewski BH. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg Infect Dis 1998; 4: 551-560.
53. Rumbaugh KP, Griswold JA, Hamood AN. The role of quorum sensing in the in vivo virulence of Pseudomonas aeruginosa. Microbes Infect 2000; 2: 1721-1731.
54. Winzer K, Williams P. Quorum sensing and the regulation of virulence gene expression in pathogenic bacteria. Int J Med Microbiol 2001; 291: 131-143.
55. Smith RS, Iglewski BH. Pseudomonas aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol 2003; 6: 56-60.
56. Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of Clinical Microbiology, 8th edn. Washington: ASM Press, 2003: 719-728.
57. Baselski V. Microbiologic diagnosis of ventilator-associated pneumonia. Infect Dis Clin North Am 1993; 7: 331-357.
58. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8: 557-584.
59. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 45: 433-436.
60. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001; 3: 255-264.
61. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1948-1953.
62. Kohler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechere JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997; 23: 345-354.
63. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 2242-2246.
64. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-3327.
65. Jo JT, Brinkman FS, Hancock RE. Aminoglycoside efflux in Pseudomonas aeruginosa. Involvement of novel outer membrane proteins. Antimicrob Agents Chemother 2003; 47: 1101-1111.
66. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am 2001; 85: 19-42.
67. Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn Microbiol Infect Dis 2001; 41: 161-163.
68. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002; 49: 229-233.
69. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999; 43: 882-889.
70. Lister PD. β-Lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy 2000; 20: S213-S218.
71. Sanders CC, Sanders WE Jr. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824-839.
72. Campbell JI, Ciofu O, Hoiby N. Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different β-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob Agents Chemother 1997; 41: 1380-1384.
73. Langaee TY, Gagnon L, Huletsky A. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC β-lactamase expression. Antimicrob Agents Chemother 2000; 44: 583-589.
74. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N. Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother 2002; 46: 3406-3411.
75. Livermore DM. Of Pseudomonas, porms, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-250.
76. Köhler T, Pechère C. In vitro selection of antibiotic resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2001; 7(suppl 5): 7-10.
77. Yoneyama H, Nakae T. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 2385-2390.
78. Pirnay JP, De Vos D, Mossialos D, Vanderkelen A, Cornelis P, Zizi M. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ Microbiol 2002; 4: 872-882.
79. Köhler T, Epp SF, Curty LK, Pechère JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999; 181: 6300-6305.
80. Ziha-Zarifi I, Llanes C, Köhler T, Pechère JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-291.
81. Saito K, Yoneyama H, Nakae T. nalB-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome. FEMS Microbiol Lett 1999; 179: 67-72.
82. Srikumar R, Paul CJ, Poole K. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 2000; 182: 1410-1414.
83. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
84. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999; 5: 865-879.
85. Bradford P. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance treat. Clin Microbiol Rev 2001; 14: 933-951.
86. Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS. An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1. J Antimicrob Chemother 2001; 48: 627-630.
87. GES-1 and a fused product of aac3-Ib /aac6′-Ib′ gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 638-645.
88. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001; 45: 2598-2603.
89. Bush K. Metallo-β-lactamases: a class apart. Clin Infect Dis 1998; 27(suppl 1): S48-S53.
90. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-331.
91. Toleman MA, Simm AM, Murphy TA et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002; 50: 673-679.
92. Docquier JD, Mugnaioli C, Luzzaro F et al. Diversity of IMP-type metallo-β-lactamases in carbapenem resistant clinical isolates of Pseudomonas spp. from Italy. In: Abstract Book. 13th European Congress of Clinical Microbiology and Infections Diseases, Glasgow, UK, 2003: 583. Published in Clin Microbiol Infect 2003; 9(suppl 1): 121.
93. GIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob Agents Chemother 2004; 48: 4654-4661.
94. Bush K. β-Lactamases of increasing clinical importance. Curr Pharm Des 1999; 5: 839-845.
95. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3: 489-495.
96. Bush K. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
97. Docquier JD, Luzzaro F, Amicosante G, Toniolo A, Rossolini GM. Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-β-lactamase and VIM-2 metallo-β-lactamase. Emerg Infect Dis 2001; 7: 910-911.
98. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(suppl 1): S93-S99.
99. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138-163.
100. Miller GH, Sabatelli FJ, Hare RS et al. The most frequent aminoglycoside resistance mechanisms - changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997; 24(suppl 1): S46-S62.
101. Bryan LE, O'Hara K, Wong S. Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 26: 250-255.
102. Nakano M, Deguchi T, Kawamura T et al. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2289-2291.
103. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001; 45: 2263-2268.
104. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998 Drugs 1991; 58(suppl 2): 11-18.
105. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001; 48: 553-555.
106. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640.
107. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-2048.
108. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-1382.
109. Calandra G, Ricci F, Wang C, Brown K. Cross-resistance and imipenem. Lancet 1986; 2: 340-341.
110. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993; 31: 927-937.
111. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38: 547-557.
112. Jaccard C, Troillet N, Harbarth S et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-2972.
113. IMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob Agents Chemother 1999; 43: 890-901.
114. VIM-2-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-β-lactamase. FEMS Microbiol Lett 2001; 195: 145-150.
115. VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 2001; 45: 546-552.
116. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother 2001; 45: 447-453.
117. Fridkin SK, Steward CD, Edwards JR et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29: 245-252.
118. Bonfiglio G, Carciotto V, Russo G et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother 1998; 41: 307-310.
119. Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz MS. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother 1999; 43: 981-982.
120. Henwood CJ, Livermore DM, James D, Warner M. Pseudomonas Study Group. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother 2001; 47: 789-799.
121. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003; 51: 347-352.
122. Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000. Diagn Microbiol Infect Dis 2003; 45: 245-250.
123. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998-2001. Antimicrob Agents Chemother 2003; 47: 1681-1688.
124. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.
125. Jones RN, Kirby H, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002; 43: 239-243.
126. Fluit AC, Verhoef J, Schmitz FJ. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY participants. Eur J Clin Microbiol Infect Dis 2000; 19: 370-374.
127. Mendes C, Turner PJ. MYSTIC Study Group (Europe). Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000). Diagn Microbiol Infect Dis 2001; 41: 191-196.
128. Hanberger H, Diekema D, Fluit A et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001; 48: 161-176.
129. Pfaller MA, Jones RN, Biedenbach DJ. MYSTIC Program Study Group. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001; 41: 177-182.
130. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program 1997-1999. Clin Infect Dis 2001; 32(suppl 2): S146-S155.
131. VIM metallo-β-lactamase determinants, Italy. Emerg Infect Dis 2000; 6: 312-313.
132. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin Infect Dis 2000; 31: 1119-1125.
133. VIM-4. J Antimicrob Chemother 2003; 51: 1409-1414.
134. Sardelic S, Pallecchi L, Punda-Polic V, Rossolini GM. Carbapenem-resistant Pseudomonas aeruginosa-carrying VIM-2 metallo-β-lactamase determinants, Croatia. Emerg Infect Dis 2003; 9: 1022-1023.
135. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011.
136. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-967.
137. Luzzaro F, Mantengoli E, Perilli M et al. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol 2001; 39: 1865-1870.
138. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-190.
139. Giamarellou H, Zissis NP, Tagari G, Bouzos J. In vitro synergistic activities of aminoglycosides and new β-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 25: 534-536.
140. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multi-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1996; 38: 287-291.
141. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis 2000; 38: 37-41.
142. Anonymous. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317: 1692-1698.
143. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-546.
144. Leibovici L, Paul M, Poznanski O et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41: 1127-1133.
145. Fainstein V, Bodey GP, Etting L et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 1983; 12(suppl A): 101-110.
146. Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156: 2121-2126.
147. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11: 7-12.
148. Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978; 24: 45-54.
149. De Jongh CA, Joshi JH, Newman KA et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80: 96-100.
150. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41(suppl D): 13-24.
151. Pizzo PA, Hathorn JW, Hiemenz J et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-558.
152. Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
153. Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100: S83-S89.
154. Hess U, Bohme C, Rey K, Senn HJ. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6: 402-409.
155. Del Favero A, Menichetti F, Martino P et al. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-1301.
156. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-242.
157. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15: 377-382.
158. Doring G, Conway SP, Heijerman HG et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
159. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001; 17: 93-96.
160. Hoiby N. New antimicrobials in the management of cystic fibrosis. J Antimicrob Chemother 2002; 49: 235-238.
161. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. J Am Med Assoc 1998; 280: 1233-1237.
162. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2920-2925.
163. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002; 34: 1047-1054.
164. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hopitalized patients. Clin Infect Dis 2002; 34: 340-345.
165. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002; 46: 854-858.
166. Regal RE, DePestel DD, VandenBussche HL. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital. Pharmacotherapy 2003; 23: 618-624.
167. Gruson D, Hilbert G, Vargas F et al. Rotation and
168. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118-124.
169. Rice LB. Successful interventions for gram-negative resistance to extended-spectrum β-lactam antiobiotics. Pharmacotherapy 1999; 19: S120-S128.
170. Widmer AF, Wenzel RP, Trilla A, Bale MJ, Jones RN, Doebbeling BN. Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hards of a health care worker. Clin Infect Dis 1993; 16: 372-376.
171. Moolenaar RL, Crutcher JM, San Toaquin VH et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did stiff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol 2000; 21: 80-85.
172. Piddock LJ, Johnson M, Ricci V, Hill SL. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998; 42: 2956-2960.
173. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001; 3: 225-236.
174. Miller LA, Ratnam K, Payne DJ. β-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001; 1: 451-458.
175. Toney JH. Metallo-β-lactamase inhibitors: could they give old antibacterials new life? Curr Opin Invest Drugs 2003; 4: 115-116.
176. Chopra I. Research and development of antibacterial agents. Curr Opin Microbiol 1998; 1: 495-501.
177. Hancock RE. Cationic antimicrobial peptides: towards clinical applications. Expert Opin Invest Drugs 2000; 9: 1723-1729.
178. Yau YH, Ho B, Tan NS, Ng ML, Ding JL. High therapeutic index of factor C Sushi peptides: potent antimicrobials against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45: 2820-2825.